TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Ireland > Playing a role in Quality Culture

Playing a role in Quality Culture

Quality Culture and your role

EudraLex, Vol. IV, Chapter 1 (Pharmaceutical Quality System) defines Good Manufacturing Practice (GMP) as the part of quality management which ensures that products are consistently produced and controlled in accordance with the quality standards appropriate to their intended use and as required by the Marketing Authorisation, Clinical Trial Authorisation or product specification.

The scope of the Pharmaceutical Quality System (PQS) applies to all stages of the product lifecycle;

  • Pharmaceutical Development- design for quality & consistency
  • Technology Transfer- transfer product/process knowledge between sites
  • Commercial Manufacturing- establishing and maintaining a state of control, and facilitating continual improvement
  • Product Discontinuation-manage the terminal stage effectively

Effective implementation of the PQS should facilitate innovation and continual improvement and strengthen the link between pharmaceutical development and manufacturing activities. Further guidance on PQS requirements can be found at the following link:

http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q10/Step4/Q10_Guideline.pdf

Quality culture plays a significant role in ensuring that an effective PQS is in place within a pharmaceutical organisation. Establishing a quality culture takes time and commitment across the organisation. In many cases it involves changing the mind-set of a pharmaceutical organisation from a compliance-led culture to an excellence-led culture of quality. Culture drives people’s behaviour, innovation and customer service.

The actions and behaviours that are displayed at a leadership level play a key role towards the successful implementation of quality culture. It is important for leaders to be seen to demonstrate the following behaviours:

  • Visibility (presence and visible management commitment, engaging with employees at all levels within the organization)
  • Voice (passion, credibility, clarity, motivation)
  • Values (ethics, model behaviours, humility)
  • Vision (strategy, unifying goals, plan, mantra)
  • Vigilance (accountability, follow through, grit)

 

Senior management should lead the process for transformational change, dedicate financial and human resources to Quality Improvement (QI), communicate progress, hold staff accountable, address resistance to change, and exhibit visible support for QI.

Middle managers and supervisors should ensure that all employees have the direct support needed and are being held accountable to QI values and behaviours.

Without leadership commitment, progress toward the desired state will diminish and likely result in relapse to the previous state.

For more on how leader actions and behaviours influence quality culture see the following link https://ispe.org/ispeak/influence-quality-culture-part-2

 

It is not just managers alone that should drive quality culture within organisations. Ideally QI should be inherently built into the cyclical performance management plans for all employees so that it is embedded across all levels of the organization. This should also include provision of ongoing training opportunities, granting authority to make decisions and eliminating fear of consequence or blame culture.

There are many ways in which QI can be encouraged and implemented and some examples include:

  • Motivate all of your employees so that they want to be part of the cultural transformation. There are two types of motivation that drive employee engagement: intrinsic and extrinsic. Intrinsic motivation is the individual desire to seek out new things and challenges, to analyse one’s capacity, to observe and to gain knowledge. It is driven from within an individual rather than relying on external pressures. Extrinsic motivation is achieved through reward, recognition and money and is less effective in achieving full employee engagement.
  • Advertise and Promote. Don’t be shy about promoting and advertising how your QI plan is progressing and demonstrating how it is contributing to the success of developing a quality culture. Organise patient talks, Quality Awareness weeks, advertise and promote on notice boards, arrange lunch and learn sessions, celebrate the successes and make them visible.
  • Teamwork and Collaboration: It is important to regularly brainstorm (across the organisation) for new and novel ideas and ways to keep employee’s interested, included and motivated. It is equally as important to gather to solve problems and share lessons learned. Collaboration between departments helps to standardize processes.

At PharmaLex, we have a team of consultants who have a large breath of experience and exposure to pharmaceutical organisations of different types and sizes. PharmaLex would be more than happy to facilitate a call with your company and help you to develop a QI plan.

If you would like further information or wish to discuss how we can tailor our services to meet your specific needs please connect with us to discuss +353 1 846 4742 or contactirl@pharmalex.com

Related posts
Why collaboration and an Integrated Product Development program are key to successful drug development
Why collaboration and an Integrated Product Development program are key to successful drug development
14th June 2022
Key Takeaways from the PDA Europe Annex 1 Workshop
Key Takeaways from the PDA Europe Annex 1 Workshop
7th June 2022
NLS DAYS 2022
NLS DAYS 2022
September 28 - May 29th, 2022
Addressing Limitations of Sterility Testing
Addressing Limitations of Sterility Testing
9th May 2022
Are virtual audits sustainable post-pandemic?
Are virtual audits sustainable post-pandemic?
6th May 2022
Orphan Drug Designation: Securing the Significant Benefits
Orphan Drug Designation: Securing the Significant Benefits
28th March 2022
Search
Upcoming Webinars

June 28th, 2022

eCTD in Australia: key steps to start a successful submission

08:30 am CET / 4:30 pm AEST

June 28th, 2022

An Introduction to Bayesian adaptive methods in clinical trials

04:00 PM CET

June 30th, 2022

Transforming the drug development process with an integrated strategy

03:00 PM CET

Categories
  • All News
  • Webinars
  • Events
Archive
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
24 Jun

Milena Shuytsova-Mircheva and Lisa Pascoe latest blog here https://www.pharmalex.com/sponsors-gear-up-for-a-smoother-process-with-ctis-but-must-first-overcome-key-hurdles/ discusses the benefit of the Clinical Trial Information System (CTIS).

💡 Interested in CTIS? Take the Phlexglobal survey to evaluate your preparation https://www.phlexglobal.com/ctis-survey

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • Thanks so much for your support over the past 30 days. Your commitment and timely communication have made working with you all a pleasant experience.

    US Biotech
    Senior QA Associate
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.






    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for